Glenmark Pharmaceuticals Limited (Glenmark Pharma), a research-led, global pharmaceutical company, has launched in India the first triple-drug fixed-dose combination (FDC) of the widely-used Teneliglipt in with Dapagliflozin and Metformin. This FDC has been launched under the brand name Zita®DM, and it contains the DPP4 inhibitor, Teneligliptin (20mg), the SGLT2 inhibitor, Dapaglifloz in, (10mg), and Metformin SR(500mg/1000mg) in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes.
Glenmark’s Zita® medicines have been benefiting 1.75 million Type 2 diabetic patients in India annually. The launch of Zita® DM, the most comprehensive glipt in the range, offers hope for Type 2 diabetic patients at every stage of treatment.
Zita® DM improves glycemic control in adult patients with high HbA1c, uncontrolled diabetes, and those requiring Teneligliptin and Dapagliflozin as separate drugs. Its cost is INR 14 per tablet per day, lowering the daily therapy cost by 30%, making it affordable. On the occasion of the launch, Alok Malik, President & Business Head ‐ India Formulations, Glenmark Pharma stated, “With this robust profile, we are positive Zita® DM will facilitate patient adherence to chronic diabetes treatments.”
